BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 95 filers reported holding BIOXCEL THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65 | -24.4% | 10,300 | -12.9% | 0.01% | -41.7% |
| Q2 2023 | $86 | – | 11,825 | +5812.5% | 0.01% | – |
| Q1 2023 | $0 | -100.0% | 200 | -89.3% | 0.00% | -100.0% |
| Q4 2022 | $20 | -99.9% | 1,867 | -44.6% | 0.00% | 0.0% |
| Q3 2022 | $33,000 | -36.5% | 3,367 | -21.1% | 0.00% | -50.0% |
| Q2 2022 | $52,000 | +40.5% | 4,267 | -54.1% | 0.00% | +100.0% |
| Q1 2022 | $37,000 | -19.6% | 9,300 | +272.0% | 0.00% | 0.0% |
| Q4 2021 | $46,000 | -48.3% | 2,500 | -16.7% | 0.00% | -50.0% |
| Q3 2021 | $89,000 | +2.3% | 3,000 | -23.1% | 0.00% | 0.0% |
| Q2 2021 | $87,000 | -38.3% | 3,900 | -3.5% | 0.00% | -42.9% |
| Q1 2021 | $141,000 | -58.8% | 4,040 | -67.9% | 0.01% | -53.3% |
| Q4 2020 | $342,000 | +37.9% | 12,600 | -49.7% | 0.02% | -6.2% |
| Q3 2020 | $248,000 | -59.1% | 25,048 | +36.1% | 0.02% | -60.0% |
| Q2 2020 | $607,000 | +291.6% | 18,406 | +25.0% | 0.04% | +400.0% |
| Q1 2020 | $155,000 | – | 14,722 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 60,000 | $151,800 | 0.16% |
| XTX Topco Ltd | 33,605 | $85,021 | 0.02% |
| Beacon Pointe Advisors, LLC | 301,735 | $763,390 | 0.01% |
| AllSquare Wealth Management LLC | 4,527 | $11,453 | 0.01% |
| Virtus ETF Advisers LLC | 4,646 | $11,754 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 27,553 | $69,709 | 0.01% |
| SeaCrest Wealth Management, LLC | 16,550 | $41,872 | 0.01% |
| Hennion & Walsh Asset Management, Inc. | 33,940 | $85,868 | 0.01% |
| Cutler Group LLC / CA | 4,000 | $50 | 0.01% |
| Capital Investment Advisory Services, LLC | 17,991 | $45,517 | 0.00% |